Clinical trials: Pemetrexed
NSCLC
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Objective: To study the effect of Jinfukang Koufuye combined with chemotherapy on preventing relapse and metastasis of early postoperative NSCLC patients.
- Trial name
- NCT03269162
- Testing
- Jinfukang Koufuye, Docetaxel, Pemetrexed
- Volunteers
- 144 people
- Sponsor
- lihegen
Pulpitis - Irreversible
Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine. .
The aim of this study was to clinically and radiographically evaluate the effectiveness of MTA, Biodentine, Platelet Rich Fibrin along with Mineral Trioxide Aggregate and Platelet Rich Fibrin along with Biodentine as pulpotomy…
- Trial name
- NCT04773886
- Testing
- Mineral trioxide aggregate, Biodentine, Platelet rich fibrin
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Maharishi Markendeswar University (Deemed to be University)
Malignant Pleural Mesothelioma
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
- Trial name
- PENINSULA (NCT06318286)
- Testing
- Lenvatinib, Pemetrexed, Cisplatin/Carboplatin
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Hyogo Medical University
Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227630
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 8 sites in Belgium, Italy and 2 more
- Volunteers
- 59 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung…
- Trial name
- NCT06305754
- Testing
- Sacituzumab tirumotecan, Pemetrexed, Carboplatin
- Where
- 156 sites in United States, Argentina and 17 more
- Volunteers
- 550 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Adenocarcinoma
TCM in the Treatment of Lung Adenocarcinoma
This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.
- Trial name
- NCT04482829
- Testing
- Jing-yan-kang Granule, PC chemotherapy and symptomatic treatment
- Volunteers
- 144 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Unspecified Adult Solid Tumor, Protocol Specific
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
RATIONALE: Vatalanib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00390000
- Testing
- vatalanib, pemetrexed disodium, pharmacological study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Lung Non-Squamous Non-Small Cell Carcinoma
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
This phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed by surgery (resectable).
- Trial name
- NCT07229339
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Nonsquamous Non-small Cell Lung Cancer
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to…
- Trial name
- NCT06173505
- Testing
- Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
- Where
- 17 sites in United States, Belgium and 6 more
- Volunteers
- 28 people
- Sponsor
- Xencor, Inc.
Advanced Urothelial Carcinoma
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based…
- Trial name
- NCT06738251
- Testing
- SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people…
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05681195
- Testing
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baptist Health South Florida
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Sensitivity
Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
- Trial name
- NCT05185544
- Testing
- Neoadjuvant pemetrexed and cisplatin chemotherapy
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087087
- Testing
- pemetrexed disodium
- Where
- 35 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Breast Neoplasms
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Pemetrexed is a multi-targeted anti-folate, that is used for non-small cell lung cancer and mesothelioma. There are several clinical studies of pemetrexed in breast cancer, but these are largely done before the wide use of…
- Trial name
- NCT03242616
- Testing
- Pemetrexed + Vinorelbine, Vinorelbine
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Non-Small-Cell Lung
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and efficacy of BI 2536 administered in combination with pemetrexed
- Trial name
- NCT02211833
- Testing
- BI 2536, Pemetrexed
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.
- Trial name
- NCT00394147
- Testing
- pemetrexed, gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with…
- Trial name
- NCT04716933
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 201 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
This is a randomized, controlled, double-blind, single-center Phase III clinical study in patients with EGFR/ALK mutation negative stage II-IIIB (N2) non-small cell lung cancer (NSCLC) after complete tumor resection.
- Trial name
- NCT04772287
- Testing
- Toripalimab
- Volunteers
- 341 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Resectable Non-small Cell Lung Cancer
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
This clinical trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Limertinib Followed by Sintilimab and Chemotherapy in resectable Stage II-IIIB EGFR-Mutant NSCLC.
- Trial name
- NEO-LISI (NCT07038460)
- Testing
- Limertinib+sintilimab+chemotherapy, Limertinib+chemotherapy, surgery
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Wen-zhao ZHONG